Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05322096 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
A Phase 2 study, sponsored by Gedeon Richter.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT05322096 is a Phase 2 study that has completed, run by Gedeon Richter. The registered enrollment target is 39 participants.
The verdict
NCT05322096, a Phase 2 study, has completed, sponsored by Gedeon Richter.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
RGH-706 is a novel, potent, and orally active MCHR1 antagonist drug candidate discovered and being developed by Gedeon Richter Plc. for weight management. This will be the first Phase 2, proof-of-concept study using RGH-706 and is the third study in the clinical development program for RGH-706. The aim of this study is to evaluate the efficacy, safety, and tolerability of RGH-706 in patients with Prader-Willi Syndrome (PWS).
Interventions
- DRUG Placebo
- DRUG RGH-706
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2022-09-22 |
| Est. Completion | 2024-04-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05322096
The ClinicalTrials.gov registry entry for NCT05322096 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gedeon Richter, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05322096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05322096 about?
NCT05322096 is a clinical study titled "Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome". RGH-706 is a novel, potent, and orally active MCHR1 antagonist drug candidate discovered and being developed by Gedeon Richter Plc. for weight management. This will be the first Phase 2, proof-of-concept study using RGH-706 and is the third study in the clinical development program for RGH-706. The...
What is the current status of trial NCT05322096?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2022-09-22. Estimated completion is 2024-04-10.
What interventions are being tested in trial NCT05322096?
The interventions under investigation include: Placebo (DRUG), RGH-706 (DRUG).
Who is sponsoring clinical trial NCT05322096?
This trial is sponsored by Gedeon Richter, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.